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Abstract
Background: Bile acid malabsorption (BAM) and bile acid-related diarrhea represent an under-recognized cause of
chronic diarrhea mainly because of limited guidance on appropriate diagnostic and laboratory tests. We aimed to
perform a systematic review of the literature in order to identify and compare the diagnostic accuracy of different
diagnostic methods for patients with BAM, despite a proven gold standard test is still lacking.
Methods: A PubMed literature review and a manual search were carried out. Relevant full papers, evaluating the
diagnostic accuracy of different methods for BAM, were assessed. Available data were analyzed to estimate the
sensitivity and specificity of each published test.
Results: Overall, more than one test was considered in published papers on BAM. The search strategy retrieved 574
articles; of these, only 16 were full papers (with a total of 2.332 patients) included in the final review. Specifically,
n = 8 studies used 75Selenium-homotaurocholic-acid-test (75SeHCAT) with a < 10% retention threshold; n = 8 studies
evaluated fasting serum 7-α-hydroxy-4-cholesten-3-one (C4); n = 3 studies involved total fecal bile acid (BA)
excretion over 48 h; n = 4 studies assessed fibroblast growth factor 19 (FGF19). 75SeHCAT showed an average
sensitivity and specificity of 87.32 and 93.2%, respectively, followed by serum C4 (85.2 and 71.1%) and total fecal BA
(66.6 and 79.3%). Fasting serum FGF19 had the lowest sensitivity and specificity (63.8 and 72.3%). All the extracted
data were associated with substantial heterogeneity.
Conclusions: Our systematic review indicates that 75SeHCAT has the highest diagnostic accuracy for BAM, followed
by serum C4 assay. The diagnostic yield of fecal BA and FGF19 assays is still under investigation. Our review
reinforces the need for novel biomarkers aimed to an objective detection of BAM and therefore improving the
management of this condition.
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Background
A chronic, watery diarrhea is a common occurrence in
patients with bile acid malabsorption (BAM), a condition
known to be characterized by significant clinical hetero-
geneity [1]. BAM is known to worsen the patients’ quality
of life and be a challenge for many healthcare services be-
cause of direct and indirect costs [2, 3]. Recently, several re-
search groups have focused their interest to altered bile
acid (BA) excretion and reabsorption as a prominent cause
of chronic diarrhea [2]. Nonetheless, the mechanisms
leading to excessive accumulation of BAs are still only
partly defined. From a physiological standpoint, BAs are
small amphipathic molecules synthesized by the liver and
secreted with meals in order to absorb dietary fats and fat-
soluble vitamins [4]. Approximately 95% of the unbound
BAs are reabsorbed through the ileal BA transporters and
travel through the portal circulation to the liver for recyc-
ling [3, 4]. After reabsorption, BAs stimulate the nuclear
farsenoid X receptor (FXR), which acts as main nuclear BA
receptor and increases fibroblast growth factor 19 (FGF19)
[3]. FGF19 is secreted from ileal enterocytes, acts as an
entero endocrine hormone to decrease hepatic BA synthe-
sis by downregulating the limiting rate enzyme, 7 α-
hydroxy-4-cholesten-3-one (C4) [5]. C4 is an important
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metabolic intermediate which controls cholesterol 7-
hydroxylase (CYP7A1), the enzyme involved in BA synthe-
sis starting from cholesterol [5]. BAM occurs when exces-
sive BAs are present in the colon as a result of an
imbalance of the entero-hepatic circulation [4].
In the clinical setting, current main methods to diagnose
BAM include the scintigraphic method 75Selenium-homo-
taurocholic acid test (75SeHCAT), the serum levels of 7-α-
hydroxy-4-cholesten-3-one (C4) and FGF19, whereas bile
acid (BA) excretion can be determined in stools over 48 h
[2, 3]. Studies using SeHCAT have identified four subtypes
of BAM generally recognized as: a) ileal disease preventing
BA reabsorption, e.g. Crohn’s disease, ileal resection, and ra-
diation ileitis (type 1); b) “primary” BAM associated with in-
creased BA production, likely playing a role in a subset of
patients with functional diarrhea and/or diarrhea-
predominant irritable bowel syndrome (IBS-D) (type 2); c)
normal terminal ileum BA re-absorption in the context of
various conditions, e.g. chronic pancreatitis, celiac disease,
post-cholecystectomy and microscopic colitis (type 3) [3];
and, finally, d) excessive hepatic BA synthesis in patients tak-
ing metformin or with hypertriglyceridemia, without any
clear source of impaired BA re-absorption (type 4) [6]. How-
ever, 75SeHCAT has many drawbacks, such as limited avail-
ability (can be performed in some tertiary referral centers),
needs a nuclear medicine unit where the patient has to be
investigated in two occasions (on day 0 and after 7 days),
has an unavoidable exposure of radiation (equivalent to 370
KBq or 280 keV) and it is also expensive. Because of these
reasons, other diagnostic methods have gained attention in
the clinical setting. Fasting serum C4 is a direct measure of
hepatic BA synthesis, while FGF19 represents an indirect
measure of ileal bile acid reabsorption and provides feedback
inhibition on hepatic BA synthesis [7, 8]. Therefore, when
BAs are reabsorbed, more FGF19 is released from the en-
terocyte and serum C4 is decreased, reflecting a decreased
hepatic BA synthesis [3, 5]. Several studies have been con-
ducted with these new biomarkers documenting the occur-
rence of BAM in patients with chronic diarrhea [9–11].
Physicians are challenged by the lack of reference
methods to establish a correct diagnosis of BAM and
treat (e.g. with cholestyramine, colesevelam or colestipol)
accordingly patients with chronic diarrhea related to this
condition [12]. Thus, the present systematic review was
intended to evaluate and compare the available evidence
on the diagnostic accuracy (i.e. sensitivity and specificity)
of different methods, in order to help physicians choos-
ing the best suitable tests to objective identification of
BAM in patients with chronic diarrhea.
Methods
Search strategy
A systematic review of the literature was performed in
order to evaluate the available data on the diagnostic
accuracy on the 75SeHCAT and compare it with other non-
invasive techniques including FGF19, C4 and total fecal BA
excretion for diagnosing BAM in patients with chronic
diarrhea. For this manuscript preparation we followed the
“Diagnostic test accuracy systematic reviews from Joanna
Briggs Institute Reviewer’s Manual” [13]. MedLine (via
PubMed) databases were searched up to June 2019.
The main search in MedLine was conducted using the
search string (“Diarrh*” OR “Irritable bowel syndrome”
OR “Inflammatory bowel disease” OR “IBS*” OR “IBD”
OR “Microscopic colitis” OR “MC” OR “Lymphocytic
colitis” OR “Collagenous colitis” OR “LC” OR “CC” OR
“Ulcerative colitis “OR “Crohn’s disease “OR “CD “OR
“UC “OR “Celiac disease “OR “Coeliac disease “OR “Bile
acid diarrhea “OR “Terminal ileitis “OR “FBD “OR
“functional dyspepsia” OR “Bile Acid Synthesis” OR
“Functional bowel disorder “OR “ileal resection” OR
“Bile acid pool” OR “Bile acid malabsorption “OR “BAM
“OR “IBAM” OR “PBAM” OR “malabsorb*” OR “Bile
Acids and Salts” OR “bile acid-gut microbiome” OR
“Primary bile acid diarrhoea “OR “Functional GI” OR
“Bile salt malabsorption“) AND (“SeHCAT” OR “Se-
HCAT” OR “75SeHCAT” OR “Se-75″ OR “75-SeHCAT”
OR “SE75“ OR “75-selenium homotaurocholic acid “OR
“selenium-labelled homotaurocholic acid test” OR
“75selenium homotaurocholic acid test “OR “75-selen-
ium homotaurocholic acid test “OR “bile salt receptor”
OR “total faecal bile acid “OR “TFBA “OR “Fecal bile
acids “OR “total faecal BA in 48h” OR “48h. total faecal
bile acid “OR “radiolabelled bile salt retention” OR “23-
seleno-25-homotaurocholic acid “OR “farnesoid X re-
ceptor “OR “FXR “OR “biomarkers for BAM” OR “fibro-
blast growth factor 19 “OR “fibroblast growth factor-19
“OR “FGF19 “OR “Serum FGF19” OR “FGF-19 “OR
“Total BA in feces “OR “Bile acids in feces “OR “Bile Salt
Hydrolase” OR “CYP7A1” OR “nuclear pregnane X re-
ceptor” OR “Se-HCAT “OR “14C-glycocholate” OR “Se-
75 “OR “selenium homocholic acid taurine “OR “preg-
nane X receptor” OR “TGR5” OR “Fecal total and indi-
vidual BAs” OR “7a-hydroxy-4-cholesten-3-one “OR “C4
“OR “Total faecal bile acid “OR “Glycocholate” OR “bile
acid precursor” OR “7αOH-4-cholesten-3-one “OR “LC-
MC” OR “Primary bile acids in a single fecal” OR “7-α-
Hydroxy-4-Cholesten-3-One “OR “7 alfa Hydroxy 4 cho-
lesten 3 one” OR “7-alfa*” OR “7-α*”) AND (“Sensitivity
“OR “Specificity “OR “Accuracy “OR “Diagnostic accur-
acy “OR “Diagnostic yield “OR “PPV “OR “NPV “OR
“Positive predictive value “OR “Negative predictive value
“OR “Overall accuracy “OR “cost-effectiveness “OR
“clinical effectiveness “OR “Clinical assessment “OR
“Reference standard “OR “True-negative “OR “True-
positive “OR “diagnostic usefulness”).
In addition, applicable keywords were used in different
combinations for manual search and bibliography of the
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selected articles in order to improve the sensitivity of the
search strategy. The search was designed and performed
by two authors (IL, FU).
Inclusion criteria and study selection
We included in the final review, studies (full-text arti-
cles) meeting the following inclusion criteria:
1) Study design: randomized controlled trials (RCT),
observational cross-sectional, case-control, pro-
spective and retrospective studies;
2) Population: studies involving human subjects above
age of 18 with chronic diarrhea;
3) Intervention: Comparing the diagnostic sensitivity
and specificity of different diagnostic tests for BAM
including 75SeHCAT, fasting serum C4, fasting
serum FGF19 and total fecal BAs;
4) Outcome: Evaluation of the diagnostic yield of
different methods for BAM.
Exclusion criteria
For this study we applied the following exclusion cri-
teria: (a) patients who presented incomplete data; (b)
history of previous surgery (i. e., vagotomy, gastrectomy
or bariatric surgery for obesity); (c) other types of enter-
opathies (including parasitic or acute diarrhea caused
from infection); (d) drop out during follow-up; (e) stud-
ies that included subjects < 18 years of age or those con-
ducted in patients with history of cholecystectomy; (f)
radiation enteritis; (g) diverticulitis; (h) Clostridium diffi-
cile infection; (i) infectious colitis; (j) ischemic colitis; (k)
neoplastic diseases including neuroendocrine tumors; (l)
laxative abuse; (m) small intestine bacterial overgrowth
(SIBO); (n) gut dysmotility; (o) immune deficiency syn-
drome; (p) carbohydrate malabsorption; (q) hyperthy-
roidism; (r) pancreatic disorders including chronic
pancreatitis, pancreatic cancers and exocrine pancreas
deficiency; (s) studies published in language different
from English; (t) abstracts / posters or letters in journals;
and, finally, (u) animal studies.
Two authors (IL and FU) screened independently titles
and abstracts of retrieved records for inclusion in the sys-
tematic review. A three-stage search strategy was per-
formed, including an initial search of the selected database
using the pre-specified search string to identify additional
relevant keywords and index terms. The second thorough
search across all included articles was performed as full
text evaluation. A final review of the reference list was
conducted to identify any missed studies.
After the screening phase, the same two reviewers in-
dependently evaluated the remaining articles to deter-
mine eligibility according to the inclusion and exclusion
criteria. Disagreements among the two reviewers were
resolved by discussion with a third senior reviewer
(RDG) until reaching a final consensus. Quality was in-
dependently appraised by the authors (RDG, UV, GC,
AC and PP). A full flowchart of the study selection
process is illustrated in Fig. 1.
Results
Search results and study description
The primary search strategy initially retrieved 574 re-
cords. Twenty additional articles were added by manual
search of relevant references and check of bibliography.
Ten records that were duplicated have been removed.
After screening titles and abstracts, a total of 533 studies
were excluded because of inappropriate / low sensitive
diagnostic tests (e.g., 14C glycocholate breath test), non-
English language, review articles, preclinical studies or
clinical studies dealing with inadequate patient selection
(e.g., those without chronic diarrhea) or wrong outcome
(i.e., patients evaluated in terms of treatment response,
not for test accuracy). Amongst the remaining 51 studies
selected for final examination, only 16 articles were in-
cluded in this systematic review because they investi-
gated the diagnostic accuracy (i.e. sensitivity and
specificity) of the diagnostic methods to objectively de-
tect BAM. Causes of exclusion at each step were sum-
marized in Fig. 1. The main findings of selected articles
have been outlined in Table 1.
Risk of bias assessment
The remaining 51 studies were critically appraised using
the “The Joanna Briggs Institute Critical Appraisal tools”
for systematic reviews. A checklist for diagnostic test ac-
curacy studies and results were summarized in Table 2
[29]. About 87.5% of the studies had a prospective de-
sign, whereas only 12.5% had a retrospective design. Ap-
proximately 50% of the studies reported the diagnosis of
BAM based on a 7-day 75SeHCAT retention test. The
other 50% of the studies has identified BAM base on C4,
FGF19 and fecal BA assay. Only 25% of the included
studies compared head-to-head 75SeHCAT vs. other
tests (“biomarkers”) for their diagnostic accuracy in the
same study design and population. The overall risk of
bias (i.e., downsizing diagnostic accuracy) was low to
moderate in all studies.
Systematic review of the overall diagnostic accuracy
The total number of patients from the included studies
were n = 2332, with n = 1520 (65%) females. The results
from the systematic review are shown in (Table 1). Stud-
ies were divided into groups according to the diagnostic
test that they used to measure BAM. A total of 8 studies
measured 75SeHCAT retention with a < 10% of cut-off
value; 8 studies assessed serum C4; 4 studies FGF19 and
3 studies determined total fecal BA in 48 h. It should be
noted that 8 studies included more than one
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measurements of interest for this systematic review and 4
(25%) studies compared directly the diagnostic accuracy
between 75SeHCAT and the other techniques (C4, FGF19
or total fecal bile acids). For each test, the diagnostic ac-
curacy was defined and directly extracted from every art-
icle included in the analysis as the sensitivity and
specificity that the indexed test has to confirmed diagnosis
of BAM in patients with chronic diarrhea associated to
main diagnoses such as functional diarrhea, IBS-D,
Crohn’s disease, ulcerative colitis and ileal resection. This
diagnostic accuracy can be interpreted as the probability
of establishing BAM in the evaluated population.
From all the studies, the highest diagnostic yield was
observed with 75SeHCAT showing an average reported
sensitivity and specificity of 87.32 and 93.2%, followed
by serum C4 with 85.2 and 71.1%, respectively. The
diagnostic accuracy of total fecal BA in 48 h reached an
average sensitivity and specificity of 66.6 and 79.3%, re-
spectively. Fasting serum FGF19 demonstrated the low-
est diagnostic yield (63.75 and 72.25% of sensitivity and
specificity). Except from C4, however, the heterogeneity
was high for all diagnostic tests indicating a high degree
of variability across the majority of studies that cannot
be explained by chance.
Diagnostic accuracy of 75SeHCAT
75SeHCAT is a technique aimed to identify the amount
of labeled radioactive Selenium (Se) retained in the body
as a result of BA reabsorption. The more conjugated Se
is retained, the least BA is lost in the intestinal lumen
(i.e., colon). Thus, Se retention of < 10% can be consid-
ered an index of BAM-related chronic diarrhea. Based
on the results of 75SeHCAT measurements BAM can be
categorized into different degrees of severity: 0–5% (se-
vere); 5–10% (moderate); and 10–15% (mild). Using
75SeHCAT with 10% retention cut-off, the range of sen-
sitivity and specificity were 59.6 to 100% (mean of
87.32%) and 80 to 100% (mean of 93.2%), respectively,
among all relevant studies. In the milestone paper by
Sciarretta et al. reported that 75SeHCAT test had a high
sensitivity and specificity (94 and 100%, respectively) in
discriminating different subsets of patients with chronic
diarrhea vs. healthy subjects [27]. Scheurlen et al. used
75SeHCAT to establish the actual occurrence of BAM in
patients with Crohn’s disease. The authors investigated a
cohort of 64 patients with Crohn’s ileitis and showed in
about 31 of them (48.4%) had a true positive tests,
whereas 33 patients (51.6%) had a negative test. How-
ever, in 21 of the latter 33 patients (63.6%) the test
Fig. 1 The selection process has been based on key steps including identification, screening, eligibility and, finally, studies actually included in
this systematic review according to the illustrated flowchart
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yielded a false negative result, since ileal inflammation
or resection was confirmed by radiology or endoscopy.
In 14 of those 21 patients with false negative test a sten-
osis of the intestinal lumen was diagnosed. In this study,
therefore, 75SeHCAT sensitivity and specificity were the
lowest reported in the literature being 59.6 and 67.2%,
respectively [30].
Subgroup analysis for diagnostic accuracy of the C4
C4 is measured by high performance liquid chromatog-
raphy in the serum of patients with suspected BAM. In
most studies, C4 concentration > 48.3 ng/mL is consid-
ered a positive cut-off to identify patients with diarrhea
attributable to BAM. This cut-off value has been applied
in eight studies with a test sensitivity and specificity ran-
ging from 74 to 97% (mean 85.2%) and 53–94% (mean
71.1%), respectively. Compared to < 10% 75SeHCAT re-
tention, Vijayvargiya et al. confirmed that serum C4
assay demonstrated 90, 79, 73, and 92% sensitivity, speci-
ficity, positive predictive value (PPV) and negative pre-
dictive value (NPV), respectively [18]. Also, higher levels
of C4 were found in patients with BAM compared to
those without BAM with sensitivity/specificity of 82 and
53% [17].
Subgroup analysis for diagnostic accuracy of the 48 h
total fecal Bas
Another test used to identify BAM is represented by the
BA assessment (via high performance liquid chromatog-
raphy) in the feces of patients with chronic diarrhea. As
in previous tests, a cut-off of primary BAs > 10% corre-
lates with increased fecal weight and rapid colonic tran-
sit [14]. Three studies based on 468 patients with IBS-D
and -C showed a sensitivity and specificity of fecal BAs
ranging from 49 to 76% (mean 66.6%) and 75–91%
(mean 79.3%). Vijayvargiya et al. found that total fecal
48-h BA alone, or in combination with percentage of
primary fecal BAs, identified patients with increased
fecal weight with an AUROC of 0.86. In contrast, pri-
mary fecal BA alone identified patients with increased
fecal weight with an AUROC of 0.73, whereas total fecal
48-h BA alone identified patients with increased colonic
transit with an AUROC of 0.65 and percentage of pri-
mary fecal BA alone identified patients with increased
colonic transit with an AUROC of 0.69 [14].
Subgroup analysis for diagnostic accuracy of the FGF19
Finally, another method to unravel BAM is FGF19 which
is measured by enzyme-linked immunosorbent assay
(ELISA) in the serum of patients with chronic diarrhea.
Notably, FGF19 has to be assed during fasting in order
to avid any change induced by meal consumption. In
our systematic review, four studies (with a total of 897
patients) provided relevant information on the
diagnostic accuracy of FGF19 with a positive cut-off
≤145 pg/mL. Compared to < 10% 75SeHCAT, the NPV
and PPV of FGF19 the sensitivity and specificity of
FGF19 as a marker of BAM ranged from 50 to 80%
(mean 63.8%) and 65–79% (mean 72.3%), respectively.
Pattni et al. [11] reported that NPV and PPV of
FGF19 ≤ 145 pg/mL for a < 10% 75SeHCAT were 82
and 61%. Lenicek et al. found that FGF19 levels at a
cut-off < 60 ng/L had a sensitivity and specificity of 80 and
68% in 466 patients with chronic diarrhea related to
Crohn’s ileitis [22].
Discussion
The present systematic review was conceived to collect
the available data from the four major diagnostic tests,
namely 75SeHCAT, C4, fecal BA assay and FGF19,
proved to have clinical validity in identifying BAM in pa-
tients with chronic diarrhea due to various causes,
mainly including functional (i.e., IBS-D, functional diar-
rhea) and inflammatory (Crohn’s disease) disorders. It
should be noted, however, that data on BAM detection
are still scarce and based mainly on small-size observa-
tional studies. Relevant calculation of the diagnostic ac-
curacy of tests for BAM with true positive, true negative,
false positive and false negative cases, which are essential
parameters to assess sensitivity and specificity, have been
reported in very few studies. Sensitivity and specificity
were directly pooled from the included studies that re-
ported diagnostic accuracy, and were shown as mean
values in our systematic review. Nonetheless, because of
the importance of this topic in daily practice and the
possibility to improve the management of patients with
chronic diarrhea, this systematic review aimed to dem-
onstrate the actual diagnostic yield of few, though well
established diagnostic tests for BAM, in patients with
chronic diarrhea. Overall, data on 75SeHCAT, C4, fecal
BA assay and FGF19 are encouraging although it should
be stressed that any available diagnostic approach does
not provide information as to whether BAs accumulate
in the intestinal lumen as a result of true malabsorption
or an increased secretion. Apart from this pathophysio-
logical aspect, current available tests for BAM detection
can provide objective information in patients with
chronic diarrhea.
The final objective of studies involving tests for BAM
should be the identification of high diagnostic accuracy,
i.e. ‘biomarker(s)’, supporting the diagnosis of this
underlying condition. The diagnostic test with the high-
est prevalence of positive results and highest diagnostic
accuracy was 75SeHCAT retention, usually < 10% as a
best cut-off. This is an external scintigraphic approach
with two phases of detection, usually at 3 h and 7 days
after oral administration of the 370 Kbq 75Se gamma-
emitting synthetic BA (homocholic acid taurine).
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75SeHCAT resulted to have an average sensitivity and
specificity of 87.32% of 93.2% [21, 23, 24]. Our data con-
firm previous analysis. In fact, another systematic review
with meta-analysis (36 studies with a total of 5028 pa-
tients with functional bowel disorder and diarrhea) esti-
mating biomarkers for BAM, Valentin et al. [31] showed
that < 10% 75SeHCAT (twenty-four studies) had the high-
est diagnostic yield (0.308 [0.247 to 0.377 CI]), followed by
C4 (six studies) (0.171 [0.134 to 0.217 CI], fecal BAs at 48
h (two studies) (0.255 [0.0.071 to 0.606 CI] and, finally,
FGF19 (three studies) (0.248 [0.147 to 0.385 CI].
75SeHCAT did not show good accuracy in detecting
BAM in patients with ileal resection. In the study of Bor-
ghede et al. [32], the authors showed that 75SeHCAT
yielded positive retention results indicative of BAM re-
gardless the length of ileal resection. In fact, 39 out of 43
Crohn’s disease patients operated on ileal resection had a
positive 75SeHCAT in a comparable percentage to that of
Crohn’s disease but without ileal surgery. Hence, one can
conclude that BAM-related chronic diarrhea in patients
with Crohn’s ileitis occurs regardless ileal resection.
The most commonly used technique to determine
BAM, 75SeHCAT, has some important limitations. First,
this diagnostic approach shows several different thresh-
olds of retention, which affect the results of the test. In a
previous systematic review of 43 studies for a total of
1223 IBS patients, 75SeHCAT retention thresholds were
as follows: 122 (10%) with < 5%; 339 (27%) with < 10%
and 163 (13%) with < 15% retention [33]. In our evalu-
ation of the diagnostic accuracy we selected a 75SeHCAT
retention rate cut-off < 10%, which is most widely ac-
cepted for the diagnosis of BAM. Notably, a 75SeHCAT
retention < 10% correlates with a faster colonic transit
time [34]. This retention threshold is believed to per-
form best in order to identify BAM in patients with
chronic diarrhea. Secondly, it is known that 75SeHCAT
is not available in many countries apart from few tertiary
referral centers. The limited availability of 75SeHCAT
prompted research to other tests for BAM, which may
be of more practical use. Thirdly, 75SeHCAT requires a
nuclear medicine department, highly expensive equip-
ment, trained personnel, it is time consuming for the pa-
tient (as the test consists of two phases of scintigraphic
recording at day 0 and after 7 days) and, last but not
least, it has an unavoidable radiation risk. Finally, about
50% of the published studies do not compare 75SeHCAT
to the new diagnostic tests.
A previous systematic review addressed the cost-
effectiveness analysis of the relationship between 75SeH-
CAT and response to cholestyramine treatment in pa-
tients with BAM. Only three studies, based on a limited
number of patients, covered this topic and the results
showed that, in the long-term, there were no consistent
cost-effective differences among the main options
including trial of treatment with cholestyramine; no use
of 75SeHCAT; use of 75SeHCAT with a 15% cut-off [35].
Therefore, the ultimate choice is upon physicians and
depending on resources available. Despite significant
heterogeneity, in a recent meta-analysis, aimed to deter-
mine the proportion of patients with BAM amongst 361
cases with watery diarrhea and previous cholecystec-
tomy, the authors showed a pooled BA diarrhea rate of
70% (95% CI 56–82%) regardless a 10% or 15% 75SeH-
CAT cut-off. Five out of eight studies (166 patients)
demonstrated that cholestyramine treatment achieved a
pooled response rate of 79% (95% CI 63 to 91%), thus
confirming the usefulness of this BA sequestrant in pa-
tients with post-cholecystectomy associated BAM [36].
The C4 and FGF19 are the two serological tests, which
can be assessed by HPLC and ELISA, respectively, to
evaluate patients with BAM related chronic diarrhea. C4
yielded very positive results showing a mean reported
sensitivity and specificity of 85.2 and 71.1%, respectively.
Although with a lower diagnostic accuracy compared to
75SeHCAT, C4 assay is increasingly tested in patients
with BAM because it is relatively simple, is not invasive,
and exhibits an appreciable diagnostic accuracy [23].
Another serum marker of BAM is given by FGF19.
The pathophysiological concept supporting this assay is
based on the evidence that elevated levels of FGF19 in-
versely correlate with C4 expression, a mechanisms lead-
ing to inhibition of BA synthesis. Thus, low serum levels
of FGF19 causes a reduced inhibition of BAs thereby
promoting BAM and related diarrhea [22, 34, 37]. Leni-
cek et al. [22] demonstrated an indirect correlation be-
tween C4 (increased) and FGF19 (decreased) levels,
suggesting that when combined these two techniques
enhance the diagnostic sensitivity of BAM. The overall
FGF19 sensitivity and specificity were 63.75 and 72.25%,
with the ROC curve analysis showing that a cut-off of
FGF19 < 145 pg/mL is a specific and sensitive marker for
BAM [22, 34, 37]. FGF19 can be assessed by commer-
cially available ELISA kits; it is an easy, non-invasive
assay, and relatively not expensive diagnostic technique.
However it should be emphasized that FGF19 levels
show significant variations due to meal consumption.
That is the reason why FGF19 should be assessed during
fasting [16].
The evaluation fecal BA excretion is based on a high-
fat (usually 100 g / day for 4 days) diet followed by the
collection of the whole amount of feces in 48 h. HPLC is
needed to evaluate BAs in fecal samples. Based on three
studies, this test showed an overall sensitivity and speci-
ficity of 66.6 79.3%, thus lower compared to 75SeHCAT
and C4, but higher than FGF19. Routine use of this diag-
nostic approach is limited by its laborious organization
(i.e. patients should adhere to a high-fat diet, stools need
to be collected in 48 h and, finally, BAs measured with
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HPLC, which is not readily available in any gastroentero-
logical center) [14, 15]. Moreover, the amount of 100 g
of dietary fat has been shown not to be able to evoke an
increased entero-hepatic circulation in any patient / sub-
ject, thus undermining their actual effectiveness as chal-
lenge dose. Finally, some authors suggested a single fecal
sample can be measured for BA assay to unravel patients
with BAM, however this approach is still far from clin-
ical application and further study is needed to test its
diagnostic accuracy [14, 15, 31].
Our systematic review has two major drawbacks,
which we would like to acknowledge. First, the lack of
real gold standard tests for BAM represents the main
reason hampering comprehensive meta-analysis studies
comparing the diagnostic accuracy of available tests for
BAM. Heterogeneity was high for all diagnostic tests, in-
dicating that included patients with different etiologies
of diarrhea caused a high degree of variability across the
majority of studies, thus lowering the specificity of the
BAM tests. Large specificity variation is also due to lack
of gold standard tests. Secondly, very few studies (only
25%) compared head-to-head the available diagnostic
methods for BAM diagnosis. In this line, it is important
to point out that methods to assess patients with an
underlying BAM are currently used in few tertiary refer-
ral centers. Despite these limitations, herein we provided
clinically useful data about the average diagnostic accur-
acy reported from each included study and the expected
prevalence of the positive test that can help physicians
to the appropriate diagnostic work-up for patients with
BAM related watery diarrhea.
Conclusions
BAM is increasingly recognized as a possible cause con-
tributing to diarrhea in patients with IBS-D, microscopic
colitis, and even IBD with or without ileal inflammation.
Consequently, there is a large unmet need in patients
with chronic diarrhea for a better diagnosis and this is
coupled with the need for better therapies. The test with
the highest diagnostic accuracy for BAM is 75SeHCAT
retention, although this test is not widely available in
many countries, needs special equipment, has radiation
exposure and it is expensive and time consuming for the
patient. Serum C4 is a relatively simple blood test, accur-
ate for patients who do not have liver disease or take sta-
tins. Also, C4 has a high diagnostic accuracy second
only to 75SeHCAT. Fecal BA measurement provides an
estimate of total BAs in the stool. Although data on this
test come from one center, few studies have so far evalu-
ated the diagnostic accuracy of this test. From the litera-
ture it seems to be a reasonable starting point to explore
the use of FGF19 and C4 as relatively simple tests ad-
ministrable to diagnose BAM in IBD patients. Patients
with FGF19 values above > 145 ng/ml are unlikely to
have BAM, and are unlikely to benefit from C4 testing,
but those with values below this threshold should be in-
vestigated with C4 and/or 75SeHCAT where available.
Secondary feedback down-regulation of colonic FXR ex-
pression represents a future option that needs validation
in well designed, large cohort prospective studies enrolling
patients with BAM. The novel tests for BAM related diar-
rhea, e.g. serum C4 and FGF19 as well as fecal BAs, should
be more widely available and performed in any patients
presenting with chronic diarrhea of unknown origin.
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